Lamivudine for the treatment of HIV

被引：30

作者：

Kumar, Princy N. ^{[1
]}

Patel, Parul ^{[2
]}

机构：

[1] Georgetown Univ, Div Infect Dis, Washington, DC 20007 USA

[2] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2010年 / 6卷 / 01期

关键词：

antiretroviral therapy; HIV; lamivudine; nucleoside reverse transcriptase inhibitor; IMMUNODEFICIENCY-VIRUS-INFECTION; ZIDOVUDINE COMBINATION THERAPY; TENOFOVIR DISOPROXIL FUMARATE; CHRONIC HEPATITIS-B; CD4 CELL COUNTS; ANTIVIRAL ACTIVITY; INITIAL TREATMENT; RESISTANT VIRUS; NAIVE PATIENTS; ABACAVIR;

D O I：

10.1517/17425250903490418

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lamivudine is a nucleoside reverse transcriptase inhibitor that is widely used for the treatment of HIV-1 infection in combination with other antiretrovirals. It is a highly effective agent that can be dosed once or twice daily due to its long intracellular half-life. it also has one of the best tolerability and long-term safety profiles among all antiretroviral agents and continues to be preferred as part of initial or subsequent combination therapy in HIV-infected patients.

引用

页码：105 / 114

页数：10

共 66 条

[11] Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults [J].

DeJesus, E ;

Herrera, G ;

Teofilo, E ;

Gerstoft, J ;

Buendia, CB ;

Brand, JD ;

Brothers, CH ;

Hernandez, J ;

Castillo, SA ;

Bonny, T ;

Lanier, ER ;

Scott, TR .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :1038-1046

[12] Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: A randomized equivalence trial [J].

DeJesus, E ;

McCarty, D ;

Farthing, CF ;

Shortino, DD ;

Grinsztejn, B ;

Thomas, DA ;

Schrader, SR ;

Castillo, SA ;

Sension, MG ;

Gough, K ;

Madison, SJ .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) :411-418

[13] Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021) [J].

Delaunay, C ;

Brun-Vézinet, F ;

Landman, R ;

Collin, G ;

Peytavin, G ;

Trylesinski, A ;

Flandre, P ;

Miller, M ;

Descamps, D .

JOURNAL OF VIROLOGY, 2005, 79 (15) :9572-9578

[14] A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].

DIENSTAG, JL ;

PERRILLO, RP ;

SCHIFF, ER ;

BARTHOLOMEW, M ;

VICARY, C ;

RUBIN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661

[15] Lamivudine as initial treatment for chronic hepatitis B in the United States [J].

Dienstag, JL ;

Schiff, ER ;

Wright, TL ;

Perrillo, RP ;

Hann, HWL ;

Goodman, Z ;

Crowther, L ;

Condreay, LD ;

Woessner, M ;

Rubin, M ;

Brown, NA .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263

[16] Histological outcome during long-term lamivudine therapy [J].

Dienstag, JL ;

Goldin, RD ;

Heathcote, EJ ;

Hann, HWL ;

Woessner, M ;

Stephenson, SL ;

Gardner, S ;

Gray, DF ;

Schiff, ER .

GASTROENTEROLOGY, 2003, 124 (01) :105-117

[17]

DUMOND JB, 2006, LANCET, V368, P476

[18] Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men [J].

Dumond, Julie B. ;

Reddy, Y. Sunila ;

Troiani, Luigi ;

Rodriguez, Jose E. ;

Bridges, Arlene S. ;

Fiscus, Susan A. ;

Yuen, Geoffrey J. ;

Cohen, Myron S. ;

Kashuba, Angela D. M. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (02) :156-162

[19] Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis [J].

Dumond, Julie B. ;

Yeh, Rosa F. ;

Patterson, Kristine B. ;

Corbett, Amanda H. ;

Jung, Byung Hwa ;

Rezk, Naser L. ;

Bridges, Arlene S. ;

Stewart, Paul W. ;

Cohen, Myron S. ;

Kashuba, Angela D. M. .

AIDS, 2007, 21 (14) :1899-1907

[20]

ERON J, 1998, 5 C RETR OPP INF INF, P151

← 1 2 3 4 5 6 7 →